David R Fogelman

List of Publications by Year
in descending order

78 papers	2,739 citations	172386 29 h-index	189801 50 g-index
80 all docs	80 docs citations	80 times ranked	4607 citing authors

#	Article	IF	Citations
1	Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors. JAMA Oncology, 2022, 8, 904.	3.4	13
2	Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Annals of Surgery, 2021, 273, 806-813.	2.1	61
3	Comprehensive Clinical and Molecular Characterization of KRAS^{G12C}-Mutant Colorectal Cancer. JCO Precision Oncology, 2021, 5, 613-621.	1.5	31
4	Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants. JAMA Oncology, 2021, 7, 693.	3.4	56
5	Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Medicine, 2021, 10, 5041-5050.	1.3	35
6	Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 1385-1394.	3.2	31
7	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Annals of Surgery, 2020, 271, 996-1002.	2.1	34
8	Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. Cancers, 2020, 12, 2636.	1.7	4
9	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2020, 155, 832.	2.2	105
10	Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clinical Colorectal Cancer, 2020, 19, e189-e199.	1.0	1
11	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clinical Colorectal Cancer, 2020, 19, 248-255.e6.	1.0	3
12	Modified gemcitabine plus nabâ€paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Medicine, 2020, 9, 5406-5415.	1.3	9
13	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research, 2020, 26, 1924-1931.	3.2	50
14	Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Investigational New Drugs, 2020, 38, 1763-1773.	1.2	3
15	A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer. Journal of Pain and Symptom Management, 2020, 59, 1052-1058.e1.	0.6	5
16	The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 3939-3947.	0.7	12
17	An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endoscopic Ultrasound, 2020, 9, 24.	0.6	23
18	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. British Journal of Cancer, 2019, 121, 505-510.	2.9	32

#	Article	IF	Citations
19	Dual-Energy X-Ray Absorptiometry Compared to Computed Tomography for Visceral Adiposity Assessment Among Gastrointestinal and Pancreatic Cancer Survivors. Scientific Reports, 2019, 9, 11500.	1.6	5
20	Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients. Scientific Reports, 2019, 9, 13966.	1.6	43
21	Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. VideoGIE, 2019, 4, 223-225.	0.3	20
22	Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma. Cancer Medicine, 2019, 8, 2867-2876.	1.3	32
23	Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas, 2019, 48, 837-843.	0.5	22
24	First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 619-627.	0.7	8
25	Physical activity and exercise during preoperative pancreatic cancer treatment. Supportive Care in Cancer, 2019, 27, 2275-2284.	1.0	45
26	The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, e15773-e15773.	0.8	5
27	A retrospective analysis of antibiotics usage and effect on overall survival and progressive free survival in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, e15781-e15781.	0.8	5
28	FOLFIRINOX in pancreatic cancer patients age 75 years or older.. Journal of Clinical Oncology, 2019, 37, 362-362.	0.8	2
29	The association between female hormonal supplementation and molecular types in colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15133-e15133.	0.8	0
30	Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors.. Journal of Clinical Oncology, 2019, 37, 3034-3034.	0.8	0
31	FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis.. Journal of Clinical Oncology, 2019, 37, e15060-e15060.	0.8	0
32	Meat consumption and BRAF mutation status in colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15135-e15135.	0.8	0
33	Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension. Oncologist, 2018, 23, 712-718.	1.9	9
34	Medical oncology and pancreatic cancer: what the radiologist needs to know. Abdominal Radiology, 2018, 43, 383-392.	1.0	2
35	Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell, 2018, 33, 752-769.e8.	7.7	58
36	Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. Journal of Gastrointestinal Surgery, 2018, 22, 703-712.	0.9	39

#	Article	IF	Citations
37	High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. Cancer Prevention Research, 2018, 11, 679-686.	0.7	25
38	Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. Journal of Hematology and Oncology, 2018, 11, 71.	6.9	30
39	Randomized, doubleâ€blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer Medicine, 2018, 7, 5382-5393.	1.3	32
40	Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.. Journal of Clinical Oncology, 2018, 36, 3549-3549.	0.8	1
41	Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer.. Journal of Clinical Oncology, 2018, 36, 12022-12022.	0.8	0
42	High prevalence of hereditary cancer syndromes and outcomes in adults with early-onset pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 4129-4129.	0.8	1
43	A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Supportive Care in Cancer, 2017, 25, 1809-1817.	1.0	26
44	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 4146-4154.	3.2	50
45	Home-based exercise during preoperative therapy for pancreatic cancer. Langenbeck's Archives of Surgery, 2017, 402, 1175-1185.	0.8	52
46	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2017, 152, 1048.	2.2	82
47	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Annals of Surgical Oncology, 2017, 24, 2031-2039.	0.7	30
48	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Journal of Gastrointestinal Surgery, 2017, 21, 164-174.	0.9	124
49	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS ONE, 2017, 12, e0183949.	1.1	25
50	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS ONE, 2017, 12, e0173345.	1.1	65
51	FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget, 2017, 8, 39268-39279.	0.8	69
52	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget, 2017, 8, 87163-87173.	0.8	0
53	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget, 2016, 7, 67495-67506.	0.8	42
54	Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 614-618.	0.6	14

#	Article	IF	Citations
55	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer, 2016, 122, 2671-2679.	2.0	49
56	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	7.7	192
57	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Journal of Gastrointestinal Surgery, 2016, 20, 1975-1985.	0.9	42
58	Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Medicine, 2016, 5, 239-247.	1.3	33
59	The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Annals of Surgical Oncology, 2015, 22, 1221-1228.	0.7	44
60	Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer, 2015, 121, 2968-2975.	2.0	22
61	Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Design, Development and Therapy, 2015, 9, 5075.	2.0	160
62	Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncology, The, 2015, 16, 695-703.	5.1	111
63	Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Annals of Surgical Oncology, 2015, 22, 2416-2423.	0.7	125
64	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2015, 76, 489-498.	1.1	59
65	Phase II study of preoperation mFOLFIRINOX and chemoradiation for high-risk resectable and borderline resectable pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, 362-362.	0.8	2
66	Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center.. Journal of Clinical Oncology, 2015, 33, 320-320.	0.8	0
67	Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabineâ€based therapy with or without bevacizumab. Cancer, 2014, 120, 1780-1786.	2.0	23
68	Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?. Pancreas, 2014, 43, 343-349.	0.5	8
69	Role of Neoadjuvant Therapy in the Multimodality Treatment of Older Patients with Pancreatic Cancer. Journal of the American College of Surgeons, 2014, 219, 111-120.	0.2	36
70	Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 307-313.	2.9	21
71	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 164-171.	1.0	108
72	The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Investigational New Drugs, 2013, 31, 1375-1383.	1.2	6

#	Article	IF	Citations
73	Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE. Blood, 2013, 122, 580-580.	0.6	27
74	The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 2012, 69, 425-430.	1.1	10
75	Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemotherapy and Pharmacology, 2011, 68, 1431-1438.	1.1	20
76	Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Research, 2011, 31, 1417-20.	0.5	78
77	Emerging drugs for colorectal cancer. Expert Opinion on Emerging Drugs, 2008, 13, 629-642.	1.0	10
78	The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 2007, 61, 167-175.	1.1	82